A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

STATUS

Recruiting
participants needed

40
sponsor

Zhejiang Cancer Hospital

Send

Updated on 19 February 2024

See if I qualify

maintenance treatment

platelet count

metastasis

neutrophil count

adenocarcinoma

irinotecan

chemoradiotherapy

fluorouracil

systemic chemotherapy

adjuvant therapy

angiogenesis inhibitor

apatinib

colorectal adenocarcinoma

adjuvant

Summary

This is an open-label, single center, non-randomized, phase trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous adenocarcinoma(MAC).

Description

Colorectal cancer contains multiple pathological types, and one of the more special pathological types is mucinous adenocarcinoma. The prognosis of patients with mucinous adenocarcinoma is not ideal.Some molecular and genetic factors may be related to the characteristics of mucinous adenocarcinoma, in which microsatellite instability and loss of mismatch repair proteins are a focus of current research. Microsatellite instability is often associated with poor differentiation and higher tumor stage. Adenocarcinoma that secretes a large amount of mucus in pathological features.so,In this study, the incidence of ORR and AEs was the main endpoint, and the efficacy and safety of Camrelizumab combined with anti-angiogenic drugs in the treatment of advanced colorectal mucinous adenocarcinoma were observed and evaluated.

Details

Condition	Colorectal Cancer, Colorectal Cancer, Rectal disorder
Age	18years - 75years
Treatment	Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
Clinical Study Identifier	NCT04446091
Sponsor	Zhejiang Cancer Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	\. Join the study voluntarily and sign the informed consent
	\. Unresectable locally advanced or metastatic colorectal mucinous adenocarcinoma or colorectal adenocarcinoma containing mucinous gland components diagnosed by histopathology or cytology
	\. Patients who have received at least first-line and above systemic chemotherapy (which may include platinum, fluorouracil, or irinotecan-based) progress or intolerance (maintenance treatment progress after first-line chemotherapy can also be included). Simultaneous chemoradiotherapy for recurrence or metastasis after surgery is considered as first-line treatment; for radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or radiochemotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, It should be counted as a failure of first-line treatment
	\. Age 18-75 years old (including boundary value, calculated on the day of signing informed consent), both men and women
	\. ECOG score 0-2 points
	\. Blood routine and liver and kidney function meet the following conditions: neutrophil count>1.5 _10^9/L, hemoglobin concentration >90g/L, platelet count>80_109/L; ALT and AST<2.0 _ULN (with liver The transferee may be <5.0_ULN)
	\. Estimated survival time> 3 months
	\. Willing to accept long-term follow-up, willing to provide tumor tissue samples, willing to provide blood samples before and after treatment
Exclusion Criteria
	\. Known predisposition of inherited or acquired bleeding and thrombosis (such as hemophiliacs, coagulopathy, thrombocytopenia, etc.)
	\. Urinary routines suggest that urine protein ++ and a confirmed 24-hour urine protein amount> 1.0 g
	\. Suffering from active infection, or unexplained fever within 7 days before medication 38.5, or baseline white blood cell count> 15109/L
	\. There are contraindications for immunotherapy (including long-term use of hormones, radiation pneumonia has not been cured and cured within 3 months, etc.)
	\. Active autoimmune diseases (such as vitiligo, psoriasis, hypothyroidism requiring hormone replacement therapy, etc.)
	\. Patients with active hepatitis B or C, HIV patients, active tuberculosis, etc
	\. Active infection requires antimicrobial treatment (for example, antibacterial drugs, antiviral drugs, antifungal drugs)
	\. Known history of allogeneic organ transplantation and history of transplanted hematopoietic stem cells
	\. Patients with interstitial lung disease or previous history of interstitial pneumonia
	\. Those who have a history of psychotropic substance abuse and are unable to quit or have mental disorders
	\. Participated in clinical trials of other anti-tumor drugs within 2 weeks before enrollment
	\. Those who have used PD-1/PD-L1 and other immunotherapy drugs before entering the group
	\. Previous or concurrently suffering from other uncured malignant tumors, cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer can be included
	\. Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraceptive measures
	\. According to the investigator's judgment, there are other factors that may affect the results of the study or lead to the forced termination of the study, such as alcoholism, drug abuse, other serious diseases (including mental illness) need to be treated together, and there are serious laboratory abnormalities , Accompanied by family or social factors, will affect the safety of the subject

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

maintenance treatment

systemic chemotherapy

adjuvant therapy

angiogenesis inhibitor

apatinib

colorectal adenocarcinoma

adjuvant

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)